Aegis. Company overview

1.

Company overview
SEPTEMBER 2022

2.

Healthcare is undergoing an
industrial revolution
END OF 19TH TO EARLY 20TH CENTURY
Rise of specialty care and
supporting physical
infrastructure including
pharma and devices
Health Care
Health Care
1.0
2.0
Health Care
Health Care
3.0
4.0
LATE 19TH CENTURY AND BEFORE
MID 20TH TO EARLY 21ST CENTURY
2020 AND BEYOND
Basic patient-clinician
Emergence of digital for
Integration of physical and
encounters, focused on
care delivery (e.g.,
digital infrastructure to
diagnosis and treatment
telehealth, remote
monitoring) and as an
enabler of delivery
infrastructure (e.g., EHR)
enable patient-centric
care, supported by
artificial intelligence and
automation

3.

Funding and innovation in health tech
and AI reflect
this transformation over the past decade
Healthcare venture funding has
...and global markets will
accelerated…
continue to grow
28
+25% CAGR
65
7
Rapid advances in
technology, regulatory
and commercial drivers
21
6
1
7
—accelerated by COVID19—have converged to
+21% CAGR
inspire innovation
9
8
1
0
1
1
There is a critical
+45% CAGR
7
window of opportunity
6
4
4
to pioneer new
4
4
U.S. healthcare venture capital fundraising ($B)
2011
2012
2013
2014
2015
2016
2017
2018
2019
2
7
Global market size
($B)
2020
2021
2020
ventures in this space
Implications
2025
DIGITAL HEALTH
Sources: Research and Markets 2021 Global AI in Healthcare Market (2020 to 2025) report; Statista Digital Health Market Forecast
HEALTHCARE AI

4.

At this inflection point, newly emerging
health tech companies are facing common
challenges
KEY CHALLENGES IN HEALTH TECH AND AI
Significant resource
Lack of access to big data
requirements
to develop and train AI
for rapid market entry
Stringent regulations around
Misaligned incentives among
privacy,
traditional health care players
consent, compliance, and data
and innovators
security
Difficulty of market
Limited access to early
validation with
funding
a large customer
The market needs a player who can bridge the many
different stakeholders today to address these
challenges

5.

create transformative
companies that deliver
and enable world-class
patient care
OUR MISSION AT AEGIS VENTURES IS TO

6.

WE ARE NOT A VC FIRM
we are a company
creation platform
01 We are company
02 We’re both operators
03 We take a concentrated
.
.
.
builders
and investors
approach to company
creation
Unlike a traditional VC, we focus
We have much more than capital to
We launch fewer companies than
most of our efforts on building
offer our portfolio companies.
other
de novo ventures, leveraging our
And we partner with entrepreneurs
venture studios, and spend more
studio resources and partnerships
shoulder-to-shoulder to ensure
time with each one to optimize
to accelerate the customized
operational and commercial
its chances of success.
business-building process.
success.

7.

Our companies achieve five
key goals
01 Patient centricity
.
We envision the patient as the core stakeholder across any
solution we develop
02 Health equity
.
We seek equity in access, quality, and affordability across
communities we serve
03 Clinical
.
We commit to the highest clinical standards, with a clinician-led
excellence
approach to innovation
04 Scientific rigor
.
We ensure our solutions deliver evidence-based impact rooted in
science
05 Commercial
.
We aspire to launch companies which can deliver enduring impact
sustainability

8.

We launch companies
through
three
different
01
02
03
.
.
.
strategies
Internal ideation and
Productization and
U.S. market entry
creation of new
commercialization of
partnerships for global
businesses
scientific
ventures
breakthroughs

9.

We launch companies through three different
strategies
01/0
Internal ideation and
creation of new
businesses
3
We take early business ideas with high potential
for impact and transform them into viable ventures.
Our company creation platform integrates the
investment, technical, and operational resources
needed to expedite the venture creation process and
improve the probability of success.

10.

We launch companies through three different
strategies
02/0
3
Productization and
commercialization of
scientific
breakthroughs
We make targeted investments in scientific discoveries,
translating them into viable ventures. This is highly
valuable to research teams in academia who lack the
commercial assets needed for successful market entry.
We also provide operational and commercialization support
for academics who have little experience implementing

11.

We launch companies through three different
strategies
03/0
U.S. market entry
partnerships for global
ventures
3
We break down commercialization barriers commonly
confronted by founding teams with promising ideas.
We also provide operational leadership and guidance
for global business teams with a proven track
record of success who plan to enter the U.S.
market.

12.

We bring both operational and financial partnerships with
Northwell Health
High-impact
ideas,
We deploy a customer-first, problem-led approach to building
companies. By listening to end users like clinicians and patients to
rigorously
drive ideation, we uncover the healthcare industry’s most critical
vetted
pain points and identify ventures with the potential to address
them.
Best-in-class
We cultivate exceptional interdisciplinary teams — clinicians,
talent
scientists, entrepreneurs, investors, creatives, commercial and
Joint venture
We work within the healthcare system, forging and leveraging
partnerships
regulatory experts —with the best leaders in the industry.
relationships with market leaders, emerging innovators, institutions,
and consumers. We bring both operational and financial partnerships with
Northwell Health, named one of the most innovative healthcare companies
of 2022 by Fast Company.
Flexible
Our internal capital pool enables us to pursue long-term, structural
permanent
theses in high magnitude opportunity areas. Freed from the burden of
capital
capital sourcing, entrepreneurs can devote their time to core business
functions, creating enduring impact without meeting artificial shortterm fund requirements.

13.

For the first time, we are bringing all key pieces
required to build
revolutionary health tech companies in a single
ecosystem
Clinicians
Commercial and
Ensuring solutions are
regulatory
grounded in real-world
practice
Scientists
Developing and
transferring cutting edge
technologies
Enabling innovative
experts
solutions and care models
Investo
Uniting ecosystem partners
rs
needed to commercialize
and scale solutions
Entrepreneurs
Technologists
Enabling a culture of
and Creatives
innovation and
experimentation
Designing and developing
cutting-edge technology
with real-world use cases

14.

Benefits of the Northwell
partnership
Top-of-funnel access to
Bottom-of-funnel
Commercialization
resources and strategic
product testing and
and
We work directly with Northwell
assets
We shorten the wide feedback loop
iteration
Northwell acts as the first customer for
leaders to understand problems across
between testing and implementation
all solutions, with an opportunity to
the health sector, to ideate on new
which many health tech startups face,
leverage successes to build commercial
businesses, with direct access to key
achieving a rapid iterative cycle that
relationships with other customers
opinion leaders and data
lets us build solutions faster
scale
opportunities

15.

Northwell At a
Glance
Hospita
ls
Feinstein
Northwell Health is among
institutes
Lenox Health Greenwhich
village
Manhattan Eye, Ear & Throat
the largest and most
Centers
Cancer
Centers
Community
Hospital
Safety Net
Partners
Ambulatory Surgery
Partnerships
Dialysis
Centers
Imaging
Centers
Lab Patient Service
Centers
Primary Care
impactful health systems
Locations
Speciality Care
Locations
Urgent Care
Centers
Donald and Barbara Zucker School
of Medicine at Hofstra/Northwell
in
the
nation.
treats an
extremely
diverse patient
It operates at an extraordinary scale,
Hofstra Northwell School of
Graduate Nursing and Physician
Assistant
Studies School of
Elmezzi
Graduate
population, and provides our ventures
Molecular Medicine at
Northwell Health
with the ideal environment for product
development and scale
01
Leading Healthcare
.
Provider
02
Extraordinary
.
Operating Scale
03
Unique Biomedical and
.
Data Science
Capabilities
Integrated health system with 23 hospitals and
Treats >2 million distinct patients annually through
Northwell's research arm, the Feinstein Institutes
over
5.5 million
for Research encompasses 50 research labs,
800 outpatient facilities
patient encounters
supporting 2,500 clinical
Largest private employer in New York State with
Over 70,000 COVID patients treated, with 17,000 treated
research studies and 5,000 staff
over
in
Landmark AI-enabled tools including Letting Sleeping
74,000 employees, including more than 32,000
the first wave of the pandemic
Patients
clinicians
Diverse service area of ~11M
Lie (Nature Digital Medicine), and the NOCOS COVID
Delivers more than 38,000 babies annually, 1% of all
calculator
births nationally
Founding member of the Truveta healthcare data
Conducts more than 2.5 million radiological studies
consortium
every year
of 17 provider systems, representing tens of

16.

Our focus areas
Aegis is focused on two areas within healthcare, identified based on their
rapid growth profiles, potential for significant impact, and ability to form
partnerships to ensure competitive edge
A
Virtual
I
We believe that the future of AI and
Care
We systematically create virtual care
automation hinges on the accessibility of
ventures that address high-value issues that
large-scale, balanced, and generalizable
patients and healthcare providers face. Our
data. And so we are focused on building
innovative approach breaks through
diverse data sources to train innovative
traditional barriers, enabling high-
models.
technology care delivery solutions.

17.

Venture Creation
Example
Founded by leading emotion scientists and AI researchers, Hume
provides the scientific tools needed to build state of the art AI
models that can understand human emotions
STARTING WITH A TEAM FROM ACADEMIA
COMMERCIALIZED PRODUCT IN <6 MONTHS
Speed to Capital and Milestone
Accomplishment
Aegis’s $5M in seed-stage funding to Hume has eliminated the burden of of
outside fundraising, allowing the team to focus fully on product development.
Dr. Alan Cowen
Dr. Dacher Keltner
CEO & Chief
Chief Scientific
Scientist
Advisor
Commercialization and Product Launch
Google and a postdoc at UC Berkeley.
scientists,
Seven years ago, he set out to develop
Dr. Keltner is a professor at the
Strategy
new computational methods of modeling
University of California, Berkeley and
emotional behavior
director of the Greater Good Science
Dr. Cowen was previously a researcher at
Among the world’s leading emotion
Center
EARLY VALIDATION FROM THE MARKET
Aegis co-developed and helped execute the commercialization and product launch
and
Execution
strategy. Additionally, Aegis leveraged its industry connectivity to
accelerate Hume’s customer outreach and business-building expertise. Hume is
now in the process of building a platform which will enable developers to
leverage Hume’s tools to build emotionally intelligent AI models.
Studio-Wide Support Throughout
Pilots
with industry leading companies (from startups to a tech
giant) in <6 months
Recognition
as winner of 2022 SXSW Startup Pitch Event in the AI, Robotics and
Voice category
Growth
Wrap-around support was provided to the Hume team, including back-office,
design, recruiting, and full-time operationalization support from one of our
operating partners to help expedite growth, allowing the team to develop an
industry leading product suite

18.

Our AI joint
venture
Our $100M partnership assembles leading medical, technology, research, and business
resources to create a first-of-its-kind platform for systematic healthcare innovation
and entrepreneurship. The platform ideates, launches and scales AI-driven companies to
address healthcare’s biggest challenges in quality, equity and cost of care.
Bringing together leaders from
TEAM
UNIQUE VALUE PROPOSITION
Aegis, Northwell and the
Fully integrated platform
industry
As the orchestrator across key functions of a venture’s launch trajectory, from
Tom
John
Chairman
Managing
Ascertai
Partner
n
Aegis Ventures
Manning
Richard
President & CEO
Mulry
Northwell
Holdings
Beadle
Mark
President,
SolazzoStrategic
Initiatives
and COO, Northwell
Health
support
operations to financial capital, Ascertain brings together internal resources, a
robust expert network, flexible capital, and extensive healthcare knowledge to
coordinate support throughout the venture-building process.
Genuine co-creation with leading partners
The joint platform is an unprecedented combination of clinicians, scientists, VC, and
and
talent
entrepreneurs
from diverse populations. From day one, Ascertain will prioritize the
development of solutions with the end user and evidence-based clinical impact at the
center.
Rapid product development and speed to
Melynda Barnes,
Mark Michalski,
Advisory
Board,
MD
Advisory Board, Ascertain
market
often, existing AI solutions are developed but never effectively executed in
Head of HC AI/ML BD, Amazon
healthcare settings.
Ascertain
Chief Medical
Officer, Ro
MD
We are actively focused on tackling the implementation gap in healthcare AI. Too

19.

The ten values that drive us
01
Think Big and Get the Big Picture
06
Invest in Yourself
.
Right
Whether you go after a big problem or small problem, startups are
.
The most important thing you can invest in is yourself. Discover
an all-consuming endeavor. Focus on ideas with enough potential
the skills and qualities that will allow you to achieve your goals
impact to justify your full time and attention.
and find tangible ways to build them every day.
02
Be Bold
07
Empower Others
.
A few game-changing ideas can compensate for numerous mistakes.
.
The most powerful force for change and impact is small groups of
Don’t let the fear of failure or uncertainty stop you from pursuing
dedicated people working collaboratively. Use your skills and
ideas that could make a profound impact.
talents to help empower and lift up those around you.
03
Bounce Back
08
Get the Details Right
.
Failure is an inevitable part of the journey to success. Talk about
.
Little things are big things, and details matter a great deal. If
failures openly, learn from mistakes, and bounce back quickly.
you don’t get the small things right, you will never be trusted
with the big ones.
04
Work Hard and Work Smart
09
Seek Excellence
.
Expertise and value are built by working hard and working smart.
.
Raise the bar for yourself and others. Cultures that set high
The few people who can do both find themselves in select company.
expectations and do not settle for less than excellence are ones
that truly innovate.
05
Ask Why
10
Maintain Integrity
.
Always think for yourself, challenge conventional wisdom, and seek
.
Do the right thing, even when no one is looking. Your word and
disconfirming information. The greatest innovators are flexible in
their thinking and open to having their minds changed often.
reputation will follow you wherever you go.

20.

Our Interdisciplinary
Team
Our rapidly growing team is best equipped to execute on our approach – leveraging our
diverse skillsets, collective commitment to drive meaningful change, and experience
commercializing healthcare AI and virtual care models.
LEADERSHIP
ADVISORS
Bill
Tom
John
Melynda Barnes,
Mark Michalski,
Chairman
Schoenfeld
Aegis
Ventures
Chairman
Manning
Ascertain
Managing Partner
Beadle
Aegis Ventures
Advisory Board,
MD
Ascertain
Chief Medical
Officer, Ro
Advisory Board, Ascertain
MD
Head of HC AI/ML BD,
Amazon
OPERATING TEAM
VENTURE CREATION TEAM
Zachary Tan
Trung
MD MMed MMSc
Venture Creation Partner
MD MPH
Ton
Venture Creation
Partner
CLINICAL TEAM
Nitya
Venture Director
Jassar
Venture
Sudarshan
Associate
Payaum
Ali Farzad
Venture
Sanatkar
Associate
Venture
Associate
Sijia Yu
Cheri
Head of Operations
Head of Talent
Peter Allen
Kennan Murphy-Sierra
Chief People Officer
Chief of Staff
Larkins
Julius Bruch
Lorel
Nazar Al
PLATFORM
Operating Partner
Sim
MD PhD
Clinical
Specialist
Gen Crawford
Adrian
J.D.
Commercial
McCullough
Operating Partner
Elizabeth
MD, MPH
Aurrecoechea
Clinical and Public Health
Specialist
Venture
Roberts
Associate
PRODUCT TEAM
Dan Towbin
Director, Strategic
Finance
Director of Strategic
Programs & Event
Operations
Taylor
Serena Wang
Sr. Technical
Gillhouse
Recruiter
Operations Analyst
INVESTMENT TEAM
Geoff
Eli Bernstein
Ryan Douglas
Kabir Gandhi
Paulina Ruta
Andrew
Head, Product
Product
Manager
Investment
Director
Investment
Director
Investment
Manager
Investment Associate
Brockenshire
Pomposelli
TECHNICAL TEAM
Christina
Marek Sirendi
Larry Han MA
Kevin
AM RN PhD
Howe
Biostatistici
an
Technical Operating
PhD
Partner
MPhil PhD
Data
Scientist
Technical Fellow
McCarville

21.

Disclai
mer
IMPORTANT NOTICES TO RECIPIENTS
These discussion materials are provided by Aegis Ventures for informational purposes only and on a confidential basis. These discussion materials are not
intended to introduce any particular opportunity or fund.
Neither these discussion materials nor the information set forth herein constitutes or shall be interpreted to constitute, a prospectus or an offer to,
or solicitation of, any person or entity in any jurisdiction for the purchase or sale of any financial instrument or as a confirmation of any
transaction. Neither these discussion materials nor the information set forth herein is intended to be provided to or may be used by any party in any
jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations. The use of these discussion materials in
certain jurisdictions may be restricted by law. If applicable law restricts delivery of these discussion materials to a prospective counterparty, and
such restrictions are not complied with, then delivery to such person is not authorized and the prospective counterparty is requested to return these
discussion materials to Aegis Ventures.
These discussion materials and any information set forth herein, whether in whole or in part, may not be disclosed to third parties, or reproduced,
without the prior written consent of Aegis Ventures. By accepting delivery, continued possession or use of these discussion materials, each recipient
agrees to the foregoing and other matters set forth in this notice, and to return these discussion materials and destroy all copies, documents,
photographs or images containing any information set forth herein immediately upon Aegis Ventures’ request. If you do not so agree, please return these
discussion materials to Aegis Ventures immediately.
The information contained herein, including without limitation, prices, forecasts, expectations and projections (if any), has been provided solely for
illustrative and reference purposes. Furthermore, such information is based on the information reasonably available at the time of the preparation of
these discussion materials. The information contained herein necessarily incorporates significant assumptions and estimates as well as factual matters,
and is subject to correction, completion, verification and amendment without notice.
The persons involved in the preparation of these discussion materials specifically reserve the right to amend or replace information appearing in these
discussion materials at any time, and undertake no obligation to update such information. No representation or warranty, expressed or implied, is or will

22.

373 Park Ave South
© 2022 — AEGIS VENTURES
NY NY 10016
hello@aegisventures.
com